Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JV3R | ISIN: US3632252025 | Ticker-Symbol: PHPN
Tradegate
06.06.25 | 10:21
1,130 Euro
-2,59 % -0,030
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
GALECTIN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GALECTIN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1401,18006.06.
1,1201,20006.06.

Aktuelle News zur GALECTIN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.05.Galectin Therapeutics GAAP EPS of -$0.151
15.05.GALECTIN THERAPEUTICS INC - 10-Q, Quarterly Report-
GALECTIN THERAPEUTICS Aktie jetzt für 0€ handeln
12.05.Galectin Therapeutics Inc.: Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress1
12.05.GALECTIN THERAPEUTICS INC - 8-K, Current Report2
31.03.Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update246NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results...
► Artikel lesen
31.03.GALECTIN THERAPEUTICS INC - 8-K, Current Report-
31.03.GALECTIN THERAPEUTICS INC - 10-K, Annual Report-
19.03.BIOXYTRAN, INC.: Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens139In Vitro studies have shown promise against viruses similar to the bird flu virus BOSTON, MASSACHUSETTS, March 19, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the "Company"), a clinical...
► Artikel lesen
05.03.GALECTIN THERAPEUTICS INC - 8-K, Current Report1
18.02.GALECTIN THERAPEUTICS INC - 8-K, Current Report1
23.01.GALECTIN THERAPEUTICS INC - 8-K, Current Report-
13.01.GALECTIN THERAPEUTICS INC - 8-K, Current Report-
26.12.24Hedge Fund and Insider Trading News: Warren Buffett, Ray Dalio, Stanley Druckenmiller, Liberty Latin America (LILA), Galectin Therapeutics Inc (GALT), and More13
20.12.24Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?5
20.12.24Why Is Galectin Stock Falling In Pre-market?-
20.12.24Galectin drops as trial for lead asset fails in MASH4
20.12.24Galectin Therapeutics Inc.: Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH391In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value While there was a favorable trend for incidence of varices in the primary end point intent-to-treat...
► Artikel lesen
20.12.24GALECTIN THERAPEUTICS INC - 8-K, Current Report-
14.11.24Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update152NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that...
► Artikel lesen
13.08.24Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update112NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1